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Abstract
Introduction—The 5A’s (Ask, Advise, Assess, Assist, and Arrange) strategy, a best-practice 
approach for cessation counseling, has been widely implemented in high-income countries for 
pregnant women; however, no studies have evaluated implementation in middle-income countries. 
The study objectives were to assess smoking patterns and receipt of 5A’s among pregnant women 
in Buenos Aires, Argentina and Montevideo, Uruguay.
Methods—Data were collected through administered questionnaires to women at delivery 
hospitalizations during October 2011–May 2012. Eligible women attended one of 12 maternity 
hospitals or 21 associated prenatal care clinics. The questionnaire included demographic data, 
tobacco use/cessation behaviors, and receipt of the 5A’s. Self-reported cessation was verified with 
saliva cotinine.
Results—Overall, of 3400 pregnant women, 32.8% smoked at the beginning of pregnancy; 
11.9% quit upon learning they were pregnant or later during pregnancy, and 20.9% smoked 
throughout pregnancy. Smoking prevalence varied by country with 16.1% and 26.7% who smoked 
throughout pregnancy in Argentina and Uruguay, respectively. Among pregnant smokers in 
Argentina, 23.8% reported that a provider asked them about smoking at more than one prenatal 
care visit; 18.5% were advised to quit; 5.3% were assessed for readiness to quit, 4.7% were 
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provided assistance, and 0.7% reported follow-up was arranged. In Uruguay, those percentages 
were 36.3%, 27.9%, 5.4%, 5.6%, and 0.2%, respectively.
Conclusions—Approximately, one in six pregnant women smoked throughout pregnancy in 
Buenos Aires and one in four in Montevideo. However, a low percentage of smokers received any 
cessation assistance in both countries. Healthcare providers are not fully implementing the 
recommended 5A’s intervention to help pregnant women quit smoking.
Introduction
Smoking during pregnancy is associated with many adverse outcomes for both the mother 
and baby including placental complications, intrauterine growth retardation, low birth 
weight, preterm birth, stillbirth, neonatal death, reduced infant lung function, infant 
neurodevelopment problems, and sudden infant death syndrome.1–4 Smoking is high among 
women of reproductive age in Argentina (13%–23%) and Uruguay (16%–22%),5,6 and 
prevalence of smoking during pregnancy is estimated to be 11% and 18%, for Argentina and 
Uruguay, respectively.7 However, it is unknown what percentage of women who smoked 
before pregnancy quit when they learn they are pregnant or later during pregnancy and 
reasons why women quit in these two countries.
Some women stop smoking spontaneously when they find out they are pregnant.7 To support 
these women and those who cannot quit on their own, clinician counseling is recommended 
by the World Health Organization,8 and has been shown to modestly increase quits and 
reduce the risk of preterm delivery and low birth weight.9 As pregnancy is a time of frequent 
contact with health professionals, healthcare providers may help to improve maternal and 
infant health by systematically identifying and providing counseling to pregnant patients 
who currently or recently used tobacco. The 5A’s (Ask, Advise, Assess, Assist, and 
Arrange) is a best-practice and evidence-based approach for delivering cessation counseling 
to all smokers.9,10 This strategy has been implemented in several countries, including low 
and middle income countries.11 Since 2011 in Argentina,12 and since 2009 in Uruguay,13 
national tobacco control programs have recommended brief cessation counseling 
interventions based on, or equivalent to, the 5A’s; however, training and resources for this 
approach have not been delivered to healthcare providers at a national level. Thus, it is 
unknown the extent to which the 5A’s for smoking cessation are being implemented by 
prenatal care providers. The study objectives are to assess smoking patterns and describe 
receipt of the 5A’s for smoking cessation during pregnancy among women attending 
prenatal care in publicly-funded clinics in Buenos Aires, Argentina and Montevideo, 
Uruguay. The data from the current study uses baseline data from a cluster randomized-
controlled trial of brief counseling to help pregnant women quit smoking. Approximately, 
99% of the childbirths in these countries are attended at maternity hospitals; 70% and 50% 
of childbirths take place in publicly-funded hospitals in Argentina and Uruguay, 
respectively, which are funded by the ministries of health and free of charge. Prenatal care is 
provided by physicians and midwives, and over 94% of pregnant women receive prenatal 
care during at least four visits during pregnancy (a mean of seven visits). Women attending 
these publicly-funded centers come from the most deprived economic sectors in both 
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countries.14,15 These data can be used to inform national tobacco control efforts and prenatal 
care practices in both countries.
Methods
Data Collection
Our study used baseline data from a cluster randomized-controlled trial prior to 
implementing a brief smoking cessation counseling intervention. Trial results are not yet 
available, but detailed methodology is published elsewhere.16 Prenatal clinics were selected 
for the main trial if they served more than 250 unique pregnant women per year, did not have 
a smoking cessation program based on the 5A’s for pregnant women, and had physicians, 
midwives or nurses as part of their clinic staff. Women were eligible for the current study if 
they attended one of 21 prenatal clinic clusters and delivered in one of 10 public hospitals in 
the Province of Buenos Aires, Argentina or one of two hospitals in Montevideo, Uruguay, 
during October 2011–May 2012. Women with mental or physical impairments that 
prevented them from being interviewed and women with a diagnosis of stillbirth at 
admission to the hospital were ineligible to participate.
All consecutively eligible women who signed an informed consent were included until a 
sample of 100–200 women per cluster was achieved, as required for the main trial.13 
Interviews were conducted face-to-face within the first 48 hours after delivery and was 
administered by trained interviewers. Data were collected on paper forms and entered in 
each country in a secure web data open source management system (OpenClinica).17
The questionnaire was adapted from a previous study on tobacco use during pregnancy 
conducted in Argentina, Uruguay and other countries in 2005,7 additional questions were 
added, and questionnaire was pilot-tested again from November 2010 to February 2011. The 
questionnaire included questions on basic demographics, prenatal care characteristics, 
tobacco use and cessation behaviors, second-hand smoke exposure, and receipt of cessation 
counseling during the prenatal care visits.
Data collectors within 12 hours after delivery asked eligible women two questions about 
their smoking status and women who reported smoking cessation as soon as they found out 
they were pregnant or later during pregnancy were asked to provide a saliva sample 
Biochemical verification was not conducted among women who reported not smoking prior 
to pregnancy or if they continued to smoke during pregnancy, as the risk of misclassification 
in these groups are likely low18 Women were asked to gently chew on the cotton swab insert 
from a Salivette (Sarstedt, Newton, NC). The Salivettes were stored in a refrigerator at the 
hospital for up to 1 month, transferred to a central freezer in each country, and shipped to the 
US Centers for Disease Control and Prevention laboratory in Atlanta, Georgia, for analysis. 
Salivary cotinine was measured by high-performance liquid chromatography atmospheric-
pressure chemical ionization tandem mass spectrometry.19,20 After analysis was completed, 
the saliva samples were disposed of accordingly.
The study was approved by the ethics committees of all participating hospitals; the Ethics 
Committee of the Ministry of Health of the Province of Buenos Aires, Argentina; the Ethics 
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Committee of the Centro de Educacion Medica e Investigaciones Clinicas “Norberto 
Quirno”; the Ethics Committee of the School of Medicine, Universidad de la Republica, 
Uruguay; and the Tulane University Institutional Review Board, United States.
Variables
Self-reported smoking during pregnancy was determined from questions about the woman’s 
smoking status before and during pregnancy. Women’s smoking status was categorized as 
nonsmokers, spontaneous quitters, late quitters or continued smokers. “Nonsmokers” were 
those who reported never smoking, tried cigarettes but did not smoke regularly, or quit 
smoking before they found out that they were pregnant. “Spontaneous quitters” were those 
who reported quitting as soon as they found out they were pregnant, were abstinent until 
delivery, and had saliva cotinine ≤10 ng/mL. “Late quitters” were those who reported 
smoking at the time they found out they were pregnant but quit later during pregnancy and 
remained abstinent until delivery, and had saliva cotinine ≤10 ng/mL.21 “Continued 
smokers” were those who reported smoking every day or some days throughout pregnancy 
or within the last week prior to delivery. Women who reported quitting during pregnancy, but 
whose measured cotinine was more than 10 ng/mL were also defined as continued smokers. 
About 10.0% of women who self-reported smoking cessation during pregnancy had 
biochemical evidence of continued smoking; detailed results are published elsewhere.22
All women, including nonsmokers, were asked about receipt of the first two steps of the 
5A’s: (1) provider screening for tobacco use (Ask) and (2) advice about the harms of 
tobacco use to themselves or to the unborn infant (Advise). Only quitters (spontaneous and 
late quitters) and continued smokers were asked about receipt of the remaining three steps of 
the 5A’s: (3) provider assessed their readiness to quit (Assess), (4) woman received 
assistance from provider (Assist), and (5) provider requested a follow-up contact with 
woman (Arrange). Assistance could have included advice on how to decrease withdrawal 
symptoms, help with the process, printed materials, referral to the quitlines,12,13 or referral 
to a health care professional for cessation assistance. For each of the 5A’s, women were 
asked whether it was provided at least one visit, at more than one visit or at all prenatal care 
visits.
Additional variables derived from the woman’s interview were maternal age, citizenship, 
marital status, highest level of education completed, work status in past year, and trimester 
of prenatal care initiation. Parity was derived from the clinical record. For spontaneous 
quitters, late quitters, and continued smokers, we also assessed number of days smoked per 
week, number of cigarettes smoked per day, quitting attempts, reasons for quitting, smoking 
initiation prior to pregnancy and intention to use tobacco after the baby was born.
Analysis
Of 3588 eligible women who were invited to participate 4.3% did not provide consent. We 
excluded three women from the analysis due to missing identification number, 25 due to 
missing information on smoking status and five due to uncompleted Case Report Forms. The 
final sample included 3400 women (94.8% of the initial sample); 1863 women (54.8%) gave 
birth in Argentina and 1537 women (45.2%) in Uruguay. We report frequencies and 
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percentages for categorical variables, and median and interquartile ranges for continuous 
variables overall and by country. Analyses were conducted using SAS version 9.3.23
Results
Of 3400 pregnant women, most were 20–34 years old (69.0%), citizens of Argentina or 
Uruguay (93.32%), married or partnered (80.3%), had completed at least 6 years of 
schooling (93.4%), unemployed in the past year (76.4%), multiparous (greater than one 
child; 64.5%), and initiated prenatal care in the first trimester (52.3%). Women who reported 
continued smoking were more likely to be single, less educated, multiparous, and living with 
at least one smoker compared to nonsmokers (Table 1).
Sixty-seven percent of the sample did not smoke and overall 32.8% of women were smokers 
at the beginning of their pregnancy. Of these, 8.3% were spontaneous quitters, 3.6% were 
late quitters, and 20.9% continued smokers (Table 1). Mean age of smoking initiation was 
similar in both countries and did not vary by group: 15.5 (3.3), 15.1 (2.6), and 15.1 (3.3) 
years old for spontaneous quitters, quitters during pregnancy and current smokers, 
respectively. Smoking prevalence varied by country, Uruguay had a higher percentage of 
women who smoked throughout the pregnancy compared to Argentina (26.7% vs. 16.1%; 
Tables 2 and 3). Overall, five out of 10 women in both countries reported living with at least 
one smoker. A detailed analysis of secondhand smoke exposure in this population is 
provided elsewhere.24
Overall in both countries, 80.0% of nonsmokers reported that they were asked about their 
smoking status, and 36.8% were advised that not smoking was the best thing they could do 
for their baby in at least one prenatal visit. However, a lower percentage of nonsmokers 
received the first 2A’s at more than one visit (Ask = 24.4%, and Advise = 12.0%) and at all 
visits (Ask = 13.3%, and Advise = 5.4%; data not shown). Among all quitters, 95.3% were 
asked their smoking status, 62.9% were advised to quit smoking, 17.8% were assessed of 
their readiness, 11.9% received assistance to quit and 3.0% received follow-up on their 
smoking in at least one visit. Lower percentages of quitters received each step of the 5A’s at 
more than one visit and at all prenatal visits (Table 4). Among smokers, 96.2% were asked 
their smoking status, 74.5% were ever advised to quit smoking, 21.9% were assessed of their 
readiness to quit, 14.2% received support to quit, and 2.7% were told to return to the clinic 
to follow up on their smoking ever during prenatal care. When we considered more than one 
visit, the percentages were 31.0%, 23.9%, 5.3%, 5.2%, and 0.4% respectively. A much lower 
percentage of smokers received each step of the 5A’s at all prenatal visits (Table 5). Since 
results were different by country, Tables 4 and 5 show the total numbers and the results by 
smoking status and country.
Among all quitters in both countries, the main reasons for quitting were being worried for 
the baby’s health or because of being pregnant (79.8%), being sick or having nausea 
(26.0%), and being worried for their own health (12.0%). In both countries less than 3% of 
all quitters reported that they quit due to advice from a health care professional, over half of 
women (53.6%) reported thinking about their baby as the most helpful tool used to quit 
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smoking and 11.5% reported chewing regular gum as a helpful cessation tools (data not 
shown).
As for women’s intention to smoke in the postpartum period, overall 20.6% of smokers 
reported they were planning to smoke as usual after delivery, 31.1% were planning smoke 
less than before, 10.5% were not going to smoke and 37.8% were unsure. Among 
spontaneous quitters, 59% reported that they were not going to smoke and 40% were not 
sure. Among late quitters, 34% were not going to smoke and 61% were unsure. Since results 
were different by country, Table 6 shows the total numbers and the results by smoking status 
and country.
Discussion
Overall, nearly one out of three pregnant women participating in our study reported smoking 
at the time they got pregnant. This percentage is similar to estimates for women of 
reproductive ages in other high-income countries25–27 and higher than prevalence estimates 
in other Latin-American countries.7,28
National surveys implemented at each country from 2009 show that 19.8% of nonpregnant 
women in Uruguay and 22.4% in Argentina smoked.6,29 However, results from our study 
implemented in the capital cities of both counties show that 26.7% and 16.1% of women 
continued to smoke throughout pregnancy in Uruguay and Argentina, respectively. One 
difference to note is that our study was conducted in the capital cities, where rates of poverty 
are high, and may not be representative of the situation in the rest of the nation. It is unclear 
why the smoking prevalence is higher in Uruguay, despite the country’s implementing 
population-based tobacco control measures since 2004. The difference in smoking 
prevalence by country was unexpected, and further research is needed to better understand 
these differences, particularly among low socioeconomic status pregnant women.
In any case these data highlight a serious public health concern and the need to eliminate 
tobacco use during pregnancy in Argentina and Uruguay. An economic evaluation of data 
provided in Argentina in 2011 estimated that the direct costs within the health system to 
attend to illness-related to smoking in the general population was $2 938 556 523.30 In 
Argentina and Uruguay, cost estimates for smoking during pregnancy are not currently 
available in order to motivate health systems to aggressively implement cessation strategies.
We also found that, on average in both countries, most women initiated smoking in 
adolescence, which suggests that prevention strategies aimed at youth are needed in addition 
to cessation interventions. Coordinated, multicomponent interventions that combine mass 
media campaigns, price increases, school-based policies and programs, and smoke-free 
policies are effective in reducing the initiation, prevalence and intensity of smoking among 
youth and young adults.31
We found that a best-practice approach to help pregnant smokers quit, the 5A’s, was not 
fully implemented in the sample clinics as recommended by country cessation guidelines. 
As previously mentioned, national guidelines in both countries recommend that providers 
ask all pregnant women about their smoking status, advise them on the benefits of quitting, 
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and provide assistance and follow-up for those who are ready to quit. While Argentina’s 
guidelines recommend brief cessation counseling at every prenatal visit, Uruguay’s 
guidelines do not specify the frequency.12,13 However, existence of guidelines does not 
necessarily imply a change in practice training all providers.32 Moreover, at the time of the 
current study, even if guidelines were published, neither Argentina nor Uruguay had yet 
conducted broad outreach and training to prenatal care providers. In both countries, low 
percentages of women reported that they were asked at more than one visit or every visit 
about their smoking status, and fewer were advised to quit smoking or given help to do so. 
This is similar to other studies where the first three As are more frequently implemented 
than the full 5A’s.33–35 Available resources, even free ones like the quitline,12,13 were rarely 
provided. Some possible explanations could include lack of clinician training on the 5A’s, 
lack of time to conduct the intervention during prenatal care, perceived resistance from 
women to quitting and concern about potential for harm to the relationship with the patient 
which has been reported in the formative research of our trial36 and in other studies 
conducted in high-income countries.37–39 A 2005 study of 300 obstetricians–gynecologists 
in Argentina showed that only 22% received training in smoking cessation counseling and 
48.5% reported insufficient knowledge to provide smoking cessation advice.40 Similar 
implementation barriers were reported by midwives in the formative research of this 
project.41 Studies show that training on the 5A’s as well as training in appropriate 
communication skills and patient-centered counseling methods such as motivational 
interviewing can improve smoking cessation.42 Thus, providing training, tools and resources 
on how to effectively implement the 5A’s are needed. In addition, healthcare systems 
changes such as provider reminders and including the 5A’s in electronic medical records 
may help to facilitate delivery of these interventions and integration into routine prenatal 
care.10 Moreover, tobacco use among physicians as in both countries their tobacco use is 
similar to that of the general population, which may hinder cessation guidelines 
implementation.43–45
Postpartum relapse to smoking may be of concern, considering 40% of women quit smoking 
during pregnancy and half of these women were unsure whether they would smoke after 
delivery. These women are in an advanced stage of change and should be a priority group for 
effective cessation strategies to prevent relapse and reduce secondhand smoke exposure 
among infants and children.24 Thus, education and relapse prevention messages (eg, adverse 
health effects of secondhand smoke exposure to infants and children) are needed, and 
prenatal intervention may need to be extended into the postpartum period to prevent relapse.
This study is not without limitations. First, receipt of the 5A’s was based on retrospective, 
self-report. However, using responses from women who received the 5A’s at more than one 
visit or all visits account reduce to recall bias. Validation was not possible as smoking 
cessation counseling was not typically documented in the clinical record in both countries. 
However, the majority of women maintained a card which documents all their prenatal care 
and women were allowed to refer to these cards when reflecting on their services. Second, 
due to limited resources, we relied on self-report to identify smoking status at the beginning 
of the pregnancy, and we were only able to biochemically verify smoking status of 
spontaneous and later quitters. However, misclassification of smoking status has been shown 
to be minimal among women who reported not smoking prior to pregnancy.18 Finally, these 
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findings may not be generalizable beyond the study participants in these two countries, as 
the public hospitals and associated prenatal care clinics tend to serve lower-income women 
compared to private hospitals in these countries.
In conclusion, a substantial percentage of women continued to smoking during pregnancy in 
Buenos Aires and Montevideo; however, the 5A’s is not being fully implemented by prenatal 
care providers, despite the existence of national recommendations. Efforts are needed to 
make available training, tools, and resources10 to encourage dissemination and 
implementation of the 5A’s in prenatal care settings to help pregnant smokers quit smoking 
and to improve the health of both mother and infant.
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